





EARNINGS CALL PRESENTATION.

SEVENUM, 7 MARCH 2023



FULL YEAR 2022 EARNINGS CALL

> LIVE FROM OUR HEADQUARTERS IN SEVENUM.





TODAY'S AGENDA.



BUSINESS PERFORMANCE.



REVIEW / UPDATE ON BUSINESS AND STRATEGY.







BUSINESS PERFORMANCE.



HIGHLIGHTS 2022: LOOKING BACK ON A SUCCESSFUL YEAR.

- GUIDANCE MET IN ALL ITS ELEMENTS. TOP AND BOTTOM LINE.
- NON-RX SALES GROWTH 17%; OVERALL SALES GROWTH 14%, PROVING THE ROBUSTNESS OF THE BUSINESS MODEL.

RECORD SALES OF EUR 1.2 BILLION; GROWTH IN ALL COUNTRIES. ACTIVE CUSTOMER BASE UP 1.4M IN 2022 TO 9.3M. HIGH CUSTOMER SATISFACTION (NPS ABOVE 70).

STRONG EXECUTION AND CONTINUED EFFICIENCY GAINS.
 Q4 ADJ. EBITDA MARGIN FOR ONGOING OPERATIONS 0.8%, UP 430BPS VS. 2021.
 FY -0.3%; WITH H1 -1.5% AND H2 0.9%.

• DEVELOPMENT OF ATTRACTIVE AREAS OF GROWTH.

NEW DISTRIBUTION CENTRE IN ITALY, MARKETPLACES IN GERMANY AND AUSTRIA, STRATEGIC INVESTMENT IN QUICK-COMMERCE PLAYER GOPULS (FIRST A), READY FOR E-RX.


• SUSTAINABILITY: DRIVING DE-CARBONISATION.

COMMITTED TO BRINGING EMISSIONS ALONG THE ENTIRE VALUE CHAIN TO NET ZERO.

WELL POSITIONED FOR A SUCCESSFUL 2023.




LOOKING BACK AT 2022 VS. THE GUIDANCE PROVIDED AT THE START OF THE YEAR. GUIDANCE MET IN ALL ITS ELEMENTS.





KEY FINANCIALS. DOUBLE-DIGIT TOTAL SALES GROWTH.






COTINUOUSLY STRONG NET PROMOTER SCORE. ACTIVE CUSTOMER BASE APPROACHING 10 MILLION.





23 MILLION ORDERS. CONTINUED HIGH SHARE FROM RETURNING CUSTOMERS.






KEY FINANCIALS: PROFIT & LOSS. POSITIVE ADJ. EBITDA IN H2.

IN MILLIONS OF EUROS. ADJUSTED NUMBERS FOR THE ONGOING BUSINESS OPERATIONS	Q4 2021	Q4 2022	Better / (Worse) than Q4 2021	Better / (Worse) than H1 2022	12M 2021	12M 2022
Sales	288	328	13.8%		1,060	1,204
Gross profit margin	24.6%	27.8%	3.2 рр	0.7 pp	25.2%	27.5%
Selling & distribution margin	(25.1)%	(23.4)%	1.7 рр	2.1 рр	(22.6)%	(24.5)%
Administrative costs margin	(3.0)%	(3.5)%	(0.5) pp	(0.3) pp	(3.1)%	(3.3)%
Adj. EBITDA margin	(3.5)%	0.8%	4.3 рр	2.3 рр	(0.5)%	(0.3)%
Adj. EBITDA	(10)	3	13		(5)	(4)


Adjustments in 2022 EUR 21.6M: EUR 14.1M (non-cash) from non applicability of IFRS 3 accounting of the 2021 business acquisitions, remainder are costs of the employee stock options programme (non-cash) and one-off external costs related to projects including acquisitions.



KEY FINANCIALS: GROSS PROFIT MARGIN. UP 2.3 PP VS. LAST YEAR'S 12M.




KEY FINANCIALS: SELLING & DISTRIBUTION RATIO. COST EFFICIENCY IN Q4 SIGNIFICANTLY BETTER VS. H1.







KEY FINANCIALS: CASH FLOW.








REVIEW / UPDATE ON STRATEGY AND BUSINESS.





STRATEGIC ACHIEVEMENTS 2022 AT A GLANCE.


- FURTHER RISE OF **CUSTOMER SATISFACTION** FROM ALREADY HIGH LEVEL.
- INCREASE IN **CAPACITY** AND **OPERATIONAL EFFICIENCY**.
- SUCCESSFUL LAUNCHES OF **MARKETPLACES**.
- STRONG COMMITMENT TO **SUSTAINABILITY**.
- PROGRESS MADE TOWARDS NATIONWIDE
 E-RX IN GERMANY.





FURTHER RISE OF CUSTOMER SATISFACTION.

- NOW EVEN **FASTER DELIVERY** ACROSS EUROPE.
- **DOUBLE-DIGIT GROWTH** STEADILY CONTINUED.
- ACTIVE CUSTOMER BASE UP FROM 7.9M TO 9.3M.
- **RETURNING CUSTOMER SHARE** IN SALES 4/5.
- HIGH NPS OF 72.
- SUCCESSFUL **REBRANDING IN ITALY** TO REDCARE.
- SHOP-APOTHEKE.COM CLEAR NO. 1 HEALTHCARE WEBSITE IN GERMANY.



SHOP APOTHEKE 17

INCREASED CAPACITY AND OPERATIONAL EFFICIENCY.

- ROBUST AND **RELIABLE PERFORMANCE** THROUGHOUT THE YEAR.
- CONTINUOUS NEW CUSTOMER ORDER RECORDS.
- **OPENING OF ITALIAN DISTRIBUTION CENTRE.** 100% OF ITALIAN ORDERS SHIPPED FROM MILAN.







shop apotheke europe n.v. Paris-aligned Target

2020-2100 XDC V3.0 Exp: 02/2024 XDC-ID 9874-2021-1442 © 2023 right-basedonscience.de **right** COMMITTED TO 1.5 DEGREES.



- **REDUCTION OF SCOPE 1 AND 2 CARBON EMISSIONS** OF 80% ACHIEVED THREE YEARS AHEAD OF PLAN.
- NEW TARGET OF **NET ZERO IN 2040**.
- MSCI ESG RATING AA.







UPDATE ON E-RX. PROGRESS MADE. READY FOR MORE.

- **MORE THAN 1.3 MILLION** E-PRESCRIPTIONS REDEEMED TO DATE. (As of 6 March 2023).
- ON AVERAGE **7,500 E-PRESCRIPTIONS** ARE REDEEMED DAILY.
- NATIONWIDE CONTINUOUS INCREASE UNTIL E-RX OBLIGATION (PROBABLY 2024).

READY FOR A FUTURE WITH E-PRESCRIPTIONS.



OUTLOOK AND GUIDANCE.





MID- TO LONG-TERM ADJ. EBITDA MARGIN OUTLOOK UNCHANGED FOR OUR CURRENT BUSINESS.

ADJ. EBITDA MARGIN IN EXCESS OF 8%.

DRIVERS:

- GROSS PROFIT MARGINS.
- MEDIA INCOME.
- MARKETING LOWER AS A PERCENTAGE OF SALES.
- OPERATIONAL AND OVERHEAD EFFICIENCIES.
- SCALE, SPECIFICALLY IN THE INTERNATIONAL SEGMENT.
- E-RX (ELECTRONIC PRESCRIPTIONS).
- MARKETPLACE / PLATFORM.



GUIDANCE FOR FULL YEAR 2023.

Π

S

NET ZERO 2040

Excluding impact from a potential surge in eprescriptions (eRx) in Germany.

10% TO 20% GROWTH IN NON-RX SALES.

 NON-RX ACCOUNTED FOR EUR 1.1 BILLION (90%) OF SALES IN 2022.


FREE CASH FLOW ZERO; BETWEEN EUR -20M AND +20M.

• FCF AS PER THE MOST COMMONLY USED DEFINITION, I.E. CASH FLOW FROM OPERATING ACTIVITIES PLUS INVESTING ACTIVITIES.

0.5% TO 2.5% ADJ. EBITDA MARGIN.

• YEAR-OVER-YEAR IMPROVEMENTS IN BOTH EFFICIENCIES AND INCOME.





TIME TO ASK QUESTIONS.



SHOP APOTHEKE 24

INVITATION.

Invitation to join a webcast on our Brand Strategy on Wednesday, 15 March at 15 h 00 pm (CET).





PRESENTATION & ANNUAL REPORT FOR DOWNLOAD ON shop-apotheke-europe.com





THANK YOU FOR YOUR TIME.